Company Overview
Snapshot
Founded in January 2011 by Orgad Laub, Sealantium Medical operates with 1–10 employees. The company has raised $11.57 million across two funding rounds, with Biotech Alliances International participating. In June 2023, Sealantium Medical announced the completion of its Phase I/II clinical study, marking a significant milestone in its product development.
Business overview
Sealantium Medical is a biosurgery company specializing in the development of advanced tissue sealants and hemostatic agents for surgical applications. Its core product, sFilm-FS™, is a proprietary biodegradable and biocompatible polymeric film containing Fibrin Sealant. This technology is designed to accelerate fluid coagulation and site adhesion, reducing the amount of Fibrin Sealant needed and improving sealing speed. The company serves the healthcare industry, particularly hospitals and critical care providers, focusing on surgical and medical technologies.
Strategic signal
In June 2023, Sealantium Medical announced the successful completion of its Phase I/II clinical study for sFilm-FS™. This milestone is crucial as it validates the safety and initial efficacy of their novel tissue sealant in a clinical setting, demonstrating promising results in controlling liver bleeding faster than market-leading products. For investors, this signals significant progress in product development and de-risking, potentially paving the way for further clinical trials and market entry in the biosurgery sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Sealantium Medical's flagship product?
- Sealantium Medical's flagship product is sFilm-FS™, a proprietary biodegradable and biocompatible polymeric film containing Fibrin Sealant designed for tissue sealing and hemostasis during surgery.
- When was Sealantium Medical founded and by whom?
- Sealantium Medical was founded in January 2011 by Orgad Laub.
- What was a key development for Sealantium Medical in June 2023?
- In June 2023, Sealantium Medical announced the completion of its Phase I/II clinical study for sFilm-FS™, which demonstrated promising early clinical results for safety and faster performance in controlling liver bleeding.
- Which firm was retained to lead a Series B capital raise?
- In November 2017, Sealantium Medical retained.
- What is the total capital raised by Sealantium Medical?
- Sealantium Medical has raised a total of $11.57 million across two funding rounds.